Literature DB >> 27353264

Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo.

Abrar K Thabit1, Marguerite L Monogue2, David P Nicolau3.   

Abstract

We assessed the pharmacokinetic profile of eravacycline, a novel antibiotic of the tetracycline class, and determined the dose in an immunocompetent murine thigh infection model that would provide free-drug exposure similar to that observed in humans after the administration of 1 mg/kg intravenously (i.v.) every 12 h (q12h). Eravacycline demonstrated a nonlinear protein-binding profile. The 2.5-mg/kg i.v. q12h dose in mice resulted in an area under the concentration-time curve for the free, unbound fraction of the drug of 1.64 mg · h/liter, which closely resembles the human exposure level.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27353264      PMCID: PMC4958217          DOI: 10.1128/AAC.00240-16

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.

Authors:  Catharine C Bulik; Dora E Wiskirchen; Ashley Shepard; Christina A Sutherland; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

Review 2.  Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines.

Authors:  Kenneth N Agwuh; Alasdair MacGowan
Journal:  J Antimicrob Chemother       Date:  2006-07-01       Impact factor: 5.790

3.  Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors:  Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore.

Authors:  Paul G Ambrose; Sujata M Bhavnani; Christopher M Rubino; Arnold Louie; Tawanda Gumbo; Alan Forrest; George L Drusano
Journal:  Clin Infect Dis       Date:  2006-11-27       Impact factor: 9.079

Review 5.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

Authors:  W A Craig
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

Review 6.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

7.  Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women.

Authors:  Kevin P Connors; Seth T Housman; J Samuel Pope; John Russomanno; Edward Salerno; Eric Shore; Susan Redican; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2014-01-27       Impact factor: 5.191

8.  Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.

Authors:  Jared L Crandon; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

9.  Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens.

Authors:  J A Sutcliffe; W O'Brien; C Fyfe; T H Grossman
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

  9 in total
  8 in total

1.  Antibacterial Efficacy of Eravacycline In Vivo against Gram-Positive and Gram-Negative Organisms.

Authors:  Marguerite L Monogue; Abrar K Thabit; Yukihiro Hamada; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 2.  Nonlinear Protein Binding: Not What You Think.

Authors:  Amelia N Deitchman; Ravi Shankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2018-04-04       Impact factor: 3.534

Review 3.  Eravacycline, a newly approved fluorocycline.

Authors:  Young Ran Lee; Caitlin Elizabeth Burton
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-06-07       Impact factor: 3.267

4.  Pharmacokinetics and Comprehensive Analysis of the Tissue Distribution of Eravacycline in Rabbits.

Authors:  Vidmantas Petraitis; Ruta Petraitiene; Bo Bo W Maung; Farehin Khan; Ieva Alisauskaite; Melanie Olesky; Joseph Newman; Abdul Mutlib; Xiaoyun Niu; Michael Satlin; Ravi S Singh; Harmut Derendorf; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

5.  Human-Simulated Antimicrobial Regimens in Animal Models: Transparency and Validation Are Imperative.

Authors:  Christian M Gill; Tomefa E Asempa; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

6.  In Vivo Pharmacodynamic Target Assessment of Eravacycline against Escherichia coli in a Murine Thigh Infection Model.

Authors:  Miao Zhao; Alexander J Lepak; Karen Marchillo; Jamie VanHecker; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

7.  Nonclinical Pharmacokinetics, Protein Binding, and Elimination of KBP-7072, an Aminomethylcycline Antibiotic, in Animal Models.

Authors:  Xiaojuan Tan; Min Zhang; Qingmei Liu; Ping Wang; Tian Zhou; Yuanju Zhu; Bin Chen; Meng Wang; Yong Xia; Vincent Benn; Fred Yang; Jay Zhang
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

8.  High-Precision Control of Plasma Drug Levels Using Feedback-Controlled Dosing.

Authors:  Netzahualcóyotl Arroyo-Currás; Gabriel Ortega; David A Copp; Kyle L Ploense; Zoe A Plaxco; Tod E Kippin; João P Hespanha; Kevin W Plaxco
Journal:  ACS Pharmacol Transl Sci       Date:  2018-10-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.